Work

Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Year: 2023

Type: review

Study designs: Systematic Review, Meta-Analysis

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2023.02.021

Authors: Mohammad Zamani, Shaghayegh Alizadeh-Tabari, Puja Chitkara, Siddharth Singh, Rohit Loomba

Institutions: Digestive Disease Research Institute, Tehran University of Medical Sciences, University of California San Diego

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Arrowhead Pharmaceuticals, NGM Biopharmaceuticals, Novo Nordisk, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences

Awards: A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?, Non-invasive screening of diabetics for advanced fibrosis due to NAFLD, Novel IL-23 inhibitor for the treatment of alcohol associated liver disease, Ancillary Studies of NAFLD and NASH in HIV infected Adults, QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD, UC San Diego Clinical and Translational Research Institute, San Diego Digestive Diseases Research Center, Clinical Research on Nonalcoholic Fatty Liver Disease, San Diego Cirrhosis Clinical Research Network

OpenAlex ID: W4323263342

FWCI: 1.012

Cites: 32

Cited by: 26

Related to: 10